I Agree

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms of Use.

PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Avacta Group PLC (AVCT)

Avacta Group PLC

Result of General Meeting
RNS Number : 6462K
Avacta Group PLC
23 April 2020
 

THE INFORMATION COMMUNICATED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

23 April 2020

Avacta Group plc

 

("Avacta", the "Group" or the "Company") 

Result of General Meeting

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents , is pleased to announce that at the general meeting held earlier today all resolutions were duly passed.

ADMISSION

 

Application has been made for the 31,944,443 ordinary shares of 10 pence each ("Ordinary Shares") to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and trading in the Ordinary Shares will commence on or around 8.00 a.m. on 24 April 2020.

 

Following Admission, the Company will have 207,981,280 Ordinary Shares in issue and shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the FCA's Disclosure Guidance and Transparency Rules.

 

Further to the subscription announced on 2 April 2020, Mahmud Kamani's Ordinary Shares will be issued to his adult son Umar Mahmud Kamani.

 

 

For further information from Avacta Group plc, please contact:

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel: +44 (0) 844 414 0452

www.avacta.com

 

 

finnCap Ltd (Nomad and Joint Broker)

Geoff Nash / Giles Rolls / Teddy Whiley - Corporate Finance

Tim Redfern - ECM

Tel: +44 (0) 207 220 0500

www.finncap.com

 

 

Zeus Capital Limited (Joint Broker)

John Goold / Rupert Woolfenden - Corporate Broking

Tel: +44 (0)203 829 5000

www.zeuscapital.co.uk

Zyme Communications  (Trade and Regional Media)

Katie Odgaard

 

Yellow Jersey  (Financial Media and IR)

Sarah Hollins

Henry Wilkinson

Tel: +44 (0)7787 502 947

katie.odgaard@zymecommunications.com  

 

Tel: +44 (0)203 004 9512

avacta@yellowjerseypr.com

 

 

About Avacta Group plc -   https://www.avacta.com

 

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer® biotherapeutics and pre|CISION™ tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company's therapeutics development activities are based in Cambridge, UK.

 

The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.

 

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal's immune response, to generate new antibodies; poor specificity in many cases; large size and cost. 

 

Avacta's pre|CISION platform, activates chemotherapy only in the tumour, thereby limiting systemic exposure and damage to healthy tissues, and thus improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. 

 

By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first drug, a pre|CISION targeted form of the standard-of-care Doxorubicin, into the clinic in late 2020.

 

Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., a collaboration with LG Chem to develop treatments for autoimmune and inflammatory diseases worth up to $310m, a partnership with ADC Therapeutics to develop Affimer drug conjugates and a joint venture in South Korea with Daewoong Pharmaceuticals to develop the next generation of stem cell therapies that incorporate Affimer immuno-modulators. Avacta actively seeks to license its proprietary platforms in a range of therapeutic areas.

 

The Avacta diagnostics business unit works with partners world-wide to develop Affimers for evaluation by those third parties with the objective of establishing royalty bearing license deals. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.

 

To register for news alerts by email go to  www.avacta.com/investor-news-email-alerts  

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMKKNBDCBKKQQB
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close